Alpha-1 antitrypsin deficiency, SZ phenotype: a rare type of a rare disease. Case report. 2014

Ana-Maria Nebunoiu, and Oana Claudia Deleanu, and Ileana Rohan, and Florin Mihălţan, and Joanna Chorostowska-Wynimko, and Ruxandra Ulmeanu

Alpha-1 antitrypsin deficiency is one of the genetic diseases with a clear impact on the structure and function of the lung, rarely diagnosed and treated. We present the case of a 51-year-old female patient, heavy smoker, known with chronic obstructive pulmonary disease (COPD) for 12 years, untreated, who was hospitalized for the first time in our clinic having symptoms of a severe COPD exacerbation. She has significant cardiac disease (rheumatic mitral disease, with previous episodes of pulmonary edema and cardiac arrest) and hepatitis B. The patient is hypoxic, with severe mixed ventilatory dysfunction. During the hospitalisation she received treatment of the exacerbation and after that she received recommendation of chronic inhaled bronchodilator and corticosteroid treatment. The test for alpha-1 antitrypsin deficiency has detected a plasma of 63 mg/dl, SZ phenotype. The patient returns for a second evaluation. Functional tests are significantly improved (despite inconsistent treatment) with the impressive improvement of FEV7 values and identification by plethysmography of a restrictive syndrome. Echocardiography identifies mitral valve changes likely rheumatic, severe pulmonary hypertension. Computer tomography was performed, highlighting discrete interstitial changes and denying the existence of emphysema. Marked increase in FEV1 values supported adding bronchial asthma to the list of diagnosis and recommendation to continue inhaled corticosteroid combination bronchodilator as treatment. The particularity of the case is the rare phenotype, association of asthma and COPD as the clinical manifestation and the presence of comorbidities, which complicates the diagnosis and prognosis.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012129 Respiratory Function Tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. Lung Function Tests,Pulmonary Function Tests,Function Test, Pulmonary,Function Tests, Pulmonary,Pulmonary Function Test,Test, Pulmonary Function,Tests, Pulmonary Function,Function Test, Lung,Function Test, Respiratory,Function Tests, Lung,Function Tests, Respiratory,Lung Function Test,Respiratory Function Test,Test, Lung Function,Test, Respiratory Function,Tests, Lung Function,Tests, Respiratory Function
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005819 Genetic Markers A phenotypically recognizable genetic trait which can be used to identify a genetic locus, a linkage group, or a recombination event. Chromosome Markers,DNA Markers,Markers, DNA,Markers, Genetic,Genetic Marker,Marker, Genetic,Chromosome Marker,DNA Marker,Marker, Chromosome,Marker, DNA,Markers, Chromosome
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid

Related Publications

Ana-Maria Nebunoiu, and Oana Claudia Deleanu, and Ileana Rohan, and Florin Mihălţan, and Joanna Chorostowska-Wynimko, and Ruxandra Ulmeanu
January 1978, Annals of internal medicine,
Ana-Maria Nebunoiu, and Oana Claudia Deleanu, and Ileana Rohan, and Florin Mihălţan, and Joanna Chorostowska-Wynimko, and Ruxandra Ulmeanu
April 2020, BMJ case reports,
Ana-Maria Nebunoiu, and Oana Claudia Deleanu, and Ileana Rohan, and Florin Mihălţan, and Joanna Chorostowska-Wynimko, and Ruxandra Ulmeanu
February 2019, Clinical biochemistry,
Ana-Maria Nebunoiu, and Oana Claudia Deleanu, and Ileana Rohan, and Florin Mihălţan, and Joanna Chorostowska-Wynimko, and Ruxandra Ulmeanu
December 1996, American journal of respiratory and critical care medicine,
Ana-Maria Nebunoiu, and Oana Claudia Deleanu, and Ileana Rohan, and Florin Mihălţan, and Joanna Chorostowska-Wynimko, and Ruxandra Ulmeanu
February 1987, Australian paediatric journal,
Ana-Maria Nebunoiu, and Oana Claudia Deleanu, and Ileana Rohan, and Florin Mihălţan, and Joanna Chorostowska-Wynimko, and Ruxandra Ulmeanu
June 2020, Current allergy and asthma reports,
Ana-Maria Nebunoiu, and Oana Claudia Deleanu, and Ileana Rohan, and Florin Mihălţan, and Joanna Chorostowska-Wynimko, and Ruxandra Ulmeanu
July 2020, American journal of respiratory and critical care medicine,
Ana-Maria Nebunoiu, and Oana Claudia Deleanu, and Ileana Rohan, and Florin Mihălţan, and Joanna Chorostowska-Wynimko, and Ruxandra Ulmeanu
August 1989, Journal of pediatric gastroenterology and nutrition,
Ana-Maria Nebunoiu, and Oana Claudia Deleanu, and Ileana Rohan, and Florin Mihălţan, and Joanna Chorostowska-Wynimko, and Ruxandra Ulmeanu
May 2002, Gut,
Ana-Maria Nebunoiu, and Oana Claudia Deleanu, and Ileana Rohan, and Florin Mihălţan, and Joanna Chorostowska-Wynimko, and Ruxandra Ulmeanu
January 1993, Missouri medicine,
Copied contents to your clipboard!